| Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring MJ Dolton, JE Ray, SCA Chen, K Ng, LG Pont, AJ McLachlan Antimicrobial agents and chemotherapy 56 (9), 4793-4799, 2012 | 336 | 2012 |
| Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration MJ Dolton, JE Ray, SCA Chen, K Ng, L Pont, AJ McLachlan Antimicrobial agents and chemotherapy 56 (11), 5503-5510, 2012 | 201 | 2012 |
| Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial SG Kelsen, IO Agache, W Soong, E Israel, GL Chupp, DS Cheung, ... Journal of allergy and clinical immunology 148 (3), 790-798, 2021 | 176 | 2021 |
| Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring MJ Dolton, JE Ray, D Marriott, AJ McLachlan Antimicrobial agents and chemotherapy 56 (6), 2806-2813, 2012 | 164 | 2012 |
| Voriconazole pharmacokinetics and exposure–response relationships: assessing the links between exposure, efficacy and toxicity MJ Dolton, AJ McLachlan International journal of antimicrobial agents 44 (3), 183-193, 2014 | 106 | 2014 |
| Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing MJ Dolton, G Mikus, J Weiss, JE Ray, AJ McLachlan Journal of Antimicrobial Chemotherapy 69 (6), 1633-1641, 2014 | 106 | 2014 |
| Fruit Juices as Perpetrators of Drug Interactions: The Role of Organic Anion–Transporting Polypeptides MJ Dolton, BD Roufogalis, AJ McLachlan Clinical Pharmacology & Therapeutics 92 (5), 622-630, 2012 | 92 | 2012 |
| Vancomycin pharmacokinetics in patients with severe burn injuries M Dolton, H Xu, E Cheong, P Maitz, P Kennedy, T Gottlieb, E Buono, ... Burns 36 (4), 469-476, 2010 | 83 | 2010 |
| Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial E Teng, PT Manser, K Pickthorn, F Brunstein, M Blendstrup, ... JAMA neurology 79 (8), 758-767, 2022 | 82 | 2022 |
| Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis MJ Dolton, RJM Brüggemann, DM Burger, AJ McLachlan Antimicrobial agents and chemotherapy 58 (11), 6879-6885, 2014 | 82 | 2014 |
| Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations PJ Colin, K Allegaert, AH Thomson, DJ Touw, M Dolton, M de Hoog, ... Clinical pharmacokinetics 58, 767-780, 2019 | 75 | 2019 |
| Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials S Ostrowitzki, T Bittner, KM Sink, H Mackey, C Rabe, LS Honig, ... JAMA neurology 79 (11), 1113-1121, 2022 | 72 | 2022 |
| Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based … MJ Dolton, V Perera, LG Pont, AJ McLachlan Antimicrobial agents and chemotherapy 58 (1), 48-54, 2014 | 45 | 2014 |
| Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer’s disease treated with escalating doses for up to 133 weeks H Guthrie, LS Honig, H Lin, KM Sink, K Blondeau, A Quartino, M Dolton, ... Journal of Alzheimer's disease 76 (3), 967-979, 2020 | 42 | 2020 |
| Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections MJ Dolton, AJ McLachlan Current opinion in infectious diseases 27 (6), 493-500, 2014 | 35 | 2014 |
| Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis M Maurer, DS Cheung, W Theess, X Yang, M Dolton, A Guttman, DF Choy, ... Journal of Allergy and Clinical Immunology 150 (6), 1517-1524, 2022 | 24 | 2022 |
| Comparative evaluation of the predictive performances of three different structural population pharmacokinetic models to predict future voriconazole concentrations A Farkas, G Daroczi, P Villasurda, M Dolton, M Nakagaki, JA Roberts Antimicrobial Agents and Chemotherapy 60 (11), 6806-6812, 2016 | 23 | 2016 |
| Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice V Perera, RR Bies, G Mo, MJ Dolton, VJ Carr, AJ McLachlan, RO Day, ... British Journal of Clinical Pharmacology 78 (4), 800-814, 2014 | 21 | 2014 |
| Clinical importance of the CYP2C19* 17 variant allele for voriconazole MJ Dolton, AJ McLachlan British journal of clinical pharmacology 71 (1), 137, 2011 | 20 | 2011 |
| Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: Lauriet C Monteiro, B Toth, F Brunstein, A Bobbala, S Datta, R Ceniceros, ... Neurology 101 (14), e1391-e1401, 2023 | 15 | 2023 |
Andrew J McLachlanUniversity of Sydney and Concord Hospital, Sydney, AustraliaGeverifieerd e-mailadres voor sydney.edu.au
